Protalix Biotherapeutics Stock Revenue
| PLX Stock | USD 1.67 0.05 2.91% |
Protalix Biotherapeutics fundamentals help investors to digest information that contributes to Protalix Biotherapeutics' financial success or failures. It also enables traders to predict the movement of Protalix Stock. The fundamental analysis module provides a way to measure Protalix Biotherapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Protalix Biotherapeutics stock.
| Last Reported | Projected for Next Year | ||
| Total Revenue | 65.5 M | 68.8 M |
Protalix | Revenue |
Protalix Biotherapeutics Company Revenue Analysis
Protalix Biotherapeutics' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Protalix Biotherapeutics Revenue | 65.49 M |
Most of Protalix Biotherapeutics' fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Protalix Biotherapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Historical and Projected quarterly revenue of Protalix
Projected quarterly revenue analysis of Protalix Biotherapeutics provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Protalix Biotherapeutics match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Protalix Biotherapeutics' stock price.
Protalix Revenue Driver Correlations
Understanding the fundamental principles of building solid financial models for Protalix Biotherapeutics is extremely important. It helps to project a fair market value of Protalix Stock properly, considering its historical fundamentals such as Revenue. Since Protalix Biotherapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Protalix Biotherapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Protalix Biotherapeutics' interrelated accounts and indicators.
| 0.04 | 0.16 | -0.12 | -0.04 | 0.21 | ||
| 0.04 | 0.77 | -0.44 | -0.15 | 0.76 | ||
| 0.16 | 0.77 | -0.33 | -0.16 | 0.63 | ||
| -0.12 | -0.44 | -0.33 | -0.21 | -0.62 | ||
| -0.04 | -0.15 | -0.16 | -0.21 | 0.32 | ||
| 0.21 | 0.76 | 0.63 | -0.62 | 0.32 |
Click cells to compare fundamentals
Protalix Revenue Historical Pattern
Today, most investors in Protalix Biotherapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Protalix Biotherapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's revenue growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Protalix Biotherapeutics revenue as a starting point in their analysis.
Protalix Biotherapeutics Revenue |
| Timeline |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Protalix Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, Protalix Biotherapeutics reported 65.49 M of revenue. This is 99.14% lower than that of the Biotechnology sector and 91.18% lower than that of the Health Care industry. The revenue for all United States stocks is 99.31% higher than that of the company.
Protalix Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Protalix Biotherapeutics' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Protalix Biotherapeutics could also be used in its relative valuation, which is a method of valuing Protalix Biotherapeutics by comparing valuation metrics of similar companies.Protalix Biotherapeutics is currently under evaluation in revenue category among its peers.
Protalix Biotherapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Protalix Biotherapeutics from analyzing Protalix Biotherapeutics' financial statements. These drivers represent accounts that assess Protalix Biotherapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Protalix Biotherapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 48.7M | 105.8M | 36.7M | 66.4M | 120.2M | 114.2M | |
| Enterprise Value | 91.8M | 151.9M | 31.2M | 82.8M | 122.8M | 116.7M |
Protalix Fundamentals
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.1 | ||||
| Profit Margin | (0.39) % | ||||
| Operating Margin | (0.18) % | ||||
| Current Valuation | 104.92 M | ||||
| Shares Outstanding | 73.63 M | ||||
| Shares Owned By Insiders | 14.53 % | ||||
| Shares Owned By Institutions | 5.20 % | ||||
| Number Of Shares Shorted | 3.1 M | ||||
| Price To Earning | (1.23) X | ||||
| Price To Book | 3.90 X | ||||
| Price To Sales | 3.33 X | ||||
| Revenue | 65.49 M | ||||
| Gross Profit | 28.05 M | ||||
| EBITDA | 11.65 M | ||||
| Net Income | 8.31 M | ||||
| Cash And Equivalents | 17.11 M | ||||
| Cash Per Share | 0.41 X | ||||
| Total Debt | 26.28 M | ||||
| Current Ratio | 1.33 X | ||||
| Book Value Per Share | 0.46 X | ||||
| Cash Flow From Operations | (1.32 M) | ||||
| Short Ratio | 22.71 X | ||||
| Earnings Per Share | (0.15) X | ||||
| Price To Earnings To Growth | (0.10) X | ||||
| Target Price | 14.0 | ||||
| Number Of Employees | 208 | ||||
| Beta | 0.67 | ||||
| Market Capitalization | 126.65 M | ||||
| Total Asset | 84.43 M | ||||
| Retained Earnings | (381.55 M) | ||||
| Working Capital | 24.4 M | ||||
| Current Asset | 59.65 M | ||||
| Current Liabilities | 10.33 M | ||||
| Net Asset | 84.43 M |
About Protalix Biotherapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Protalix Biotherapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Protalix Biotherapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Protalix Biotherapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Protalix Stock Analysis
When running Protalix Biotherapeutics' price analysis, check to measure Protalix Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protalix Biotherapeutics is operating at the current time. Most of Protalix Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Protalix Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protalix Biotherapeutics' price. Additionally, you may evaluate how the addition of Protalix Biotherapeutics to your portfolios can decrease your overall portfolio volatility.